TXA effective in reducing blood loss and transfusion in TKA vs. routine hemostasis .
This report has been verified
by one or more authors of the
original publication.
Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial
Arch Orthop Trauma Surg. 2015 Jul;135(7):1017-25150 patients undergoing primary total knee arthroplasty (TKA) were randomized to receive 1 g of topical tranexamic acid (TXA), 2 g of intravenous TXA, or routine hemostasis. The purpose of the study was to determine which TXA administration modality more effectively reduced total blood loss 24 post-surgery and the need for subsequent blood transfusions. Findings indicated that although a significant reduction in 24h postoperative blood loss and need for blood transfusion was seen with tranexamic acid administration, no differences were seen between topical and intravenous administration techniques.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
